Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Aliskiren | The risk or severity of hypotension, hyperkalemia, and nephrotoxicity can be increased when Aliskiren is combined with Cilazaprilat. |
| Allopurinol | The risk of a hypersensitivity reaction to Allopurinol is increased when it is combined with Cilazaprilat. |
| Aprotinin | Aprotinin may decrease the antihypertensive activities of Cilazaprilat. |
| Azathioprine | The risk or severity of myelosuppression, anemia, and severe leukopenia can be increased when Cilazaprilat is combined with Azathioprine. |
| Dapagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Dapagliflozin is combined with Cilazaprilat. |
| Canagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Canagliflozin is combined with Cilazaprilat. |
| Ertugliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Ertugliflozin is combined with Cilazaprilat. |
| Empagliflozin | The risk or severity of renal failure, hypotension, and hyperkalemia can be increased when Empagliflozin is combined with Cilazaprilat. |
| Dapoxetine | Dapoxetine may increase the orthostatic hypotensive activities of Cilazaprilat. |
| Drospirenone | Cilazaprilat may increase the hyperkalemic activities of Drospirenone. |
| Eplerenone | Eplerenone may increase the hyperkalemic activities of Cilazaprilat. |
| Everolimus | The risk or severity of adverse effects can be increased when Everolimus is combined with Cilazaprilat. |
| Sirolimus | The risk or severity of adverse effects can be increased when Sirolimus is combined with Cilazaprilat. |
| Ardeparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Ardeparin. |
| Heparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Heparin. |
| Enoxaparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Enoxaparin. |
| Sulodexide | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Sulodexide. |
| Semuloparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Semuloparin. |
| Danaparoid | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Danaparoid. |
| Dalteparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Dalteparin. |
| Tinzaparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Tinzaparin. |
| Nadroparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Nadroparin. |
| Bemiparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Bemiparin. |
| Parnaparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Parnaparin. |
| Reviparin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Reviparin. |
| Icatibant | Icatibant may decrease the antihypertensive activities of Cilazaprilat. |
| Lithium hydroxide | The serum concentration of Lithium hydroxide can be increased when it is combined with Cilazaprilat. |
| Lithium citrate | The serum concentration of Lithium citrate can be increased when it is combined with Cilazaprilat. |
| Lithium carbonate | The serum concentration of Lithium carbonate can be increased when it is combined with Cilazaprilat. |
| Temsirolimus | The risk or severity of angioedema can be increased when Temsirolimus is combined with Cilazaprilat. |
| Tizanidine | The risk or severity of hypotension can be increased when Tizanidine is combined with Cilazaprilat. |
| Tolvaptan | Tolvaptan may increase the hyperkalemic activities of Cilazaprilat. |
| Trimethoprim | Trimethoprim may increase the hyperkalemic activities of Cilazaprilat. |
| Sodium aurothiomalate | The risk or severity of hypotension, nitritoid reactions, facial flushing, nausea, and vomiting can be increased when Cilazaprilat is combined with Sodium aurothiomalate. |
| Nicorandil | Nicorandil may increase the vasodilatory activities of Cilazaprilat. |
| Sacubitril | The risk or severity of angioedema can be increased when Cilazaprilat is combined with Sacubitril. |
| Ciprofloxacin | The risk or severity of hyperkalemia can be increased when Cilazaprilat is combined with Ciprofloxacin. |
| Iron | The risk or severity of adverse effects can be decreased when Iron is combined with Cilazaprilat. |
| Icosapent | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Icosapent is combined with Cilazaprilat. |
| Mesalazine | The risk or severity of renal failure can be increased when Mesalazine is combined with Cilazaprilat. |
| Indomethacin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indomethacin is combined with Cilazaprilat. |
| Nabumetone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nabumetone is combined with Cilazaprilat. |
| Ketorolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketorolac is combined with Cilazaprilat. |
| Tenoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tenoxicam is combined with Cilazaprilat. |
| Celecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Celecoxib is combined with Cilazaprilat. |
| Tolmetin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tolmetin is combined with Cilazaprilat. |
| Rofecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Rofecoxib is combined with Cilazaprilat. |
| Piroxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Piroxicam is combined with Cilazaprilat. |
| Fenoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenoprofen is combined with Cilazaprilat. |
| Valdecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Valdecoxib is combined with Cilazaprilat. |
| Diclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diclofenac is combined with Cilazaprilat. |
| Sulindac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulindac is combined with Cilazaprilat. |
| Flurbiprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Flurbiprofen is combined with Cilazaprilat. |
| Etodolac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etodolac is combined with Cilazaprilat. |
| Mefenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Mefenamic acid is combined with Cilazaprilat. |
| Naproxen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Naproxen is combined with Cilazaprilat. |
| Sulfasalazine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Sulfasalazine is combined with Cilazaprilat. |
| Phenylbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Phenylbutazone is combined with Cilazaprilat. |
| Carprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Carprofen is combined with Cilazaprilat. |
| Diflunisal | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Diflunisal is combined with Cilazaprilat. |
| Salicylic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylic acid is combined with Cilazaprilat. |
| Meclofenamic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Meclofenamic acid is combined with Cilazaprilat. |
| Oxaprozin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxaprozin is combined with Cilazaprilat. |
| Ketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ketoprofen is combined with Cilazaprilat. |
| Balsalazide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Balsalazide is combined with Cilazaprilat. |
| Ibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuprofen is combined with Cilazaprilat. |
| Olsalazine | The risk or severity of renal failure can be increased when Olsalazine is combined with Cilazaprilat. |
| Lumiracoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lumiracoxib is combined with Cilazaprilat. |
| Magnesium salicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Magnesium salicylate is combined with Cilazaprilat. |
| Salsalate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salsalate is combined with Cilazaprilat. |
| Choline magnesium trisalicylate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Choline magnesium trisalicylate is combined with Cilazaprilat. |
| Antrafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antrafenine is combined with Cilazaprilat. |
| Aminophenazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aminophenazone is combined with Cilazaprilat. |
| Antipyrine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Antipyrine is combined with Cilazaprilat. |
| Tiaprofenic acid | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Tiaprofenic acid is combined with Cilazaprilat. |
| Etoricoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etoricoxib is combined with Cilazaprilat. |
| Taxifolin | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Taxifolin is combined with Cilazaprilat. |
| Oxyphenbutazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Oxyphenbutazone is combined with Cilazaprilat. |
| Licofelone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Licofelone is combined with Cilazaprilat. |
| Nimesulide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Nimesulide is combined with Cilazaprilat. |
| Benoxaprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benoxaprofen is combined with Cilazaprilat. |
| Zomepirac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zomepirac is combined with Cilazaprilat. |
| Cimicoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Cimicoxib is combined with Cilazaprilat. |
| Lornoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Lornoxicam is combined with Cilazaprilat. |
| Aceclofenac | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Aceclofenac is combined with Cilazaprilat. |
| Zaltoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Zaltoprofen is combined with Cilazaprilat. |
| Azapropazone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Azapropazone is combined with Cilazaprilat. |
| Parecoxib | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with Cilazaprilat. |
| Salicylamide | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Salicylamide is combined with Cilazaprilat. |
| Kebuzone | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Kebuzone is combined with Cilazaprilat. |
| Isoxicam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Isoxicam is combined with Cilazaprilat. |
| Indoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Indoprofen is combined with Cilazaprilat. |
| Ibuproxam | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Ibuproxam is combined with Cilazaprilat. |
| Floctafenine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Floctafenine is combined with Cilazaprilat. |
| Fenbufen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Fenbufen is combined with Cilazaprilat. |
| Etofenamate | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Etofenamate is combined with Cilazaprilat. |
| Epirizole | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Epirizole is combined with Cilazaprilat. |
| Benzydamine | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Benzydamine is combined with Cilazaprilat. |
| Dexibuprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexibuprofen is combined with Cilazaprilat. |
| Dexketoprofen | The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Dexketoprofen is combined with Cilazaprilat. |